Moreinformation clarifies chase field is available hotels near chase field examines at Publisher: Chicago ReviewPress; Second edition (June 1, 2009) 464 pages ISBN-13: 978-1556528330$29.95 (CAN $32.95) SOURCE: Hamline University School of LawMedia contact:Cynthia Bielke651-523-3169 (office)651-683-1910 (cell)Email ContactCopyright 2009, Market Wire, All rights reserved.-0-. NEW YORK, May 29 (Reuters) - JPMorgan Chase & Co (JPM.N) onFriday lowered its profit per share figures by 2 cents to 5cents for each of the previous five years to reflect a newaccounting rule Net income remained unchanged. Stocks  |  Regulatory News  |  Bonds  |  Funds News  |  ETFs News The second-largest U.S. bank said the change calls forcompanies to include some stock-based compensation awards thathave yet to vest when calculating shares outstanding. It said the change does not affect the bank's net income,financial position or regulatory capital for the affectedperiods. JPMorgan lowered net income per share to $1.35 from $1.37for 2008, to $4.33 from $4.38 for 2007, to $4.00 from $4.04 for2006, to $2.35 from $2.38 for 2005, and to $1.52 from $1.55 for2004.

The New York-based bank disclosed the change in a U.S.Securities and Exchange Commission filing chase field seating chart . (Reporting by Jonathan Stempel; editing by John Wallace) Stocks Regulatory News Bonds Funds News ETFs News chase field layout . - Interim Results from EXPLORE Trial to be Presented at ASCO Annual Meeting - CHESHIRE, Conn.--(Business Wire)--Paroxysmal nocturnal hemoglobinuria (PNH) cells are present in the majority ofpatients with myelodysplastic syndromes (MDS), aplastic anemia (AA), and otherbone marrow failure syndromes (BMF), according to interim results from 5,285patients enrolled in the EXPLORE trial hotels close to chase field . EXPLORE (EXamination of PNH, by Level OfCD59 on REd and white blood cells) is the first large multicenter study todetermine the frequency of PNH cells in these patient populations using acentral laboratory conducting a high sensitivity test for PNH cells chase field pictures . Thefindings from EXPLORE will be presented tomorrow at the 45th Annual Meeting ofthe American Society of Clinical Oncology (ASCO).

The EXPLORE trial wassponsored by Alexion Pharmaceuticals, Inc (Nasdaq:ALXN) chase field events . PNH cells are defined as blood stem cells lacking certain proteins, known asGPI-anchored proteins, which include proteins that ordinarily protect bloodcells from destruction by complement, a component of the normal immune system.The lack of these complement inhibitors results in the hemolysis (red blood celldestruction) that characterizes PNH, an ultra-rare, debilitating andlife-threatening disease chase field hotels . "The true prevalence of PNH cells in patients with a number of bone marrowfailure syndromes has been unclear due to variability in PNH testing chase field az . Interimresults from the EXPLORE trial show that PNH cells are common in thesepatients," said Azra Raza, M.D., Director, MDS Program, St Vincent`sComprehensive Cancer Center, New York hotels near chase field . "These results show that high sensitivitytesting may help physicians detect undiagnosed PNH in patients with bone marrowfailure disorders, and identify those patients with bone marrow failure who maybe more likely to respond to immunosuppressive therapy." Dr. Raza is the senior author of a poster titled, "Prevalence of ParoxysmalNocturnal Hemoglobinuria (PNH) Cells in Patients with Myelodysplastic Syndromes(MDS), Aplastic Anemia (AA) or Other Bone Marrow Failure Syndromes (BMF):Interim Results from the EXPLORE Trial." The poster will be presented onSaturday, May 30 from 8:00 a.m.

to noon in West Hall C on Level 2 of the OrangeCounty Convention Center in Orlando, Fla chase field baseball . Interim results from the EXPLORE trial are based on 5,285 patients with evidenceof bone marrow failure, including 4,433 with MDS, 451 with AA, and 351 withother bone marrow failure syndromes (including patients with more than onediagnosis) chase field layout . To eliminate variability in the detection and reporting of PNH cellpopulations, a central laboratory employed a commercially availablehigh-sensitivity flow cytometry test to identify GPI anchor-deficient PNH redblood cells and white blood cells, resulting in 0.01% sensitivity hotels close to chase field . Interimresults are as follows:* PNH cells were present in 70% of patients with AA, 55% of patients with MDS,and 55% of patients with other BMF syndromes when tested at a sensitivity of0.01% PNH cells . * PNH clones of clinical significance (?1% of white blood cells) were found in25% of patients with AA (113 of 451), 1% of patients with MDS (54 of 4,433) and5% of patients with other BMF syndromes (16 of 351). * Among patients with PNH clones of clinical significance, elevated levels ofhemolysis, or red blood cell destruction, were evident in 38% of patients withAA, 44% of patients with MDS, and 69% of patients with other BMF syndromes. InPNH, excessive hemolysis can lead to thrombosis, pulmonary hypertension, kidneyfailure, pain and fatigue in affected patients.